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The use of azithromycin (AZ) for slowing the progression of lung disease in patients
with cystic ﬁbrosis (CF) is recognized nowadays. We have previously shown that one
year of AZ treatment was associated with a decrease in respiratory exacerbations
and number of antibiotic courses. The aim of this study was to conﬁrm these results
in a long term open-labelled trial in children with CF.
Methods. Fifty seven children receiving AZ for at least 2 yrs (mean age:
10.7±3.5 yrs) out of the 152 patients followed in our CF center were included
in this open-labelled trial. At months −12, 0, +12, +24 (month 0 being the start
of AZ), the following data were extracted from the software e-muco: lung function
parameters, Body Mass Index (BMI) z-score, sputum bacteriology, number of acute
pulmonary exacerbations and of oral and intravenous antibiotic courses.
Results. The relative changes in lung function and BMI z-scores at months +12 and
+24 were not different from month 0. The number of pulmonary exacerbations per
patient was reduced from 3.9±2.1 during the year prior to AZ to 2.6±1.4 in the
year after treatment (p = 0.004). This decrease was also observed for the number of
oral antibiotic courses (3.5±2.5 vs 1.4±1.3, p = 0.003) but not for the intravenous
antibiotic courses. No change in sputum bacteriology was observed, except a trend
for a decrease in methicillin-sensible Staphylococcus aureus colonization (p = 0.08).
Conclusion. This open-labelled prospective study conﬁrms the beneﬁt of AZ in
young patients with CF with regard to the decrease respiratory exacerbations and
antibiotic courses.
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Twice daily inhalation of TOBI® has become the standard of care for CF patients
infected with Pseudomonas aeruginosa (PA) which requires 30−40 minutes of treat-
ment time each day. Coupled with chest physiotherapy and mucolytic inhalations,
adherence to recommended therapy is a challenge in many patients who cite time
limitations as the excuse. The purpose of this study was to see if we could deliver
the equivalent lung dose of tobramycin but much faster. Sixteen males 10−34 years
with CF (FEV1 between 54 and 106% pred) who were currently or had recently
been using inhaled tobramycin because of infection with PA inhaled either 150mg
(1.5mL) of a new tobramycin nebuliser solution using a investigational eFlow®
nebuliser system or TOBI® (300mg /5mL) using a PARI LC PLUS® nebuliser
mixed with the radiolabel 99mTc-DTPA.
The investigational eFlow® nebuliser delivered 46.6±9.9mg of tobramycin
(mean±SD) in 4.0±1.0 minutes compared to 46.2±10.3mg in 17.0±2.2 minutes
using an PARI LC PLUS® nebuliser. There was a signiﬁcant difference in time
(p< 0.0001, paired t test) but in no other parameter including central vs peripheral
deposition and both treatments were tolerated equally. These data indicate that the
investigational eFlow® can deliver equivalent amounts of tobramycin to the lungs
as the PARI LC PLUS® nebulising TOBI® but much more rapidly which could
save up 30 minutes a day in treatment time. This shorter time requirement may
result in increased adherence to recommended therapy.
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Introduction: The aim of this study was to evaluate performances of nebulizers
with a new antibiotic (Erempharma, Levallois-Perret) for CF patients. Material and
method: LC Sprint jet (Pari, Germany) and Idehaler Pocket mesh (DTF, France)
nebulizers were tested in adult and child models. Eﬂow rapid mesh nebulizer (Pari,
Germany) was tested in adult model and NL9M jet nebulizer (DTF, France) was
tested in child model. Particle size was measured with a laser diffraction method.
Inhalable fraction was measured by a ﬁltering method using a sinus pump to
modelize adult (mouthpiece; 450ml, 40/60, 20/min) and child (facemask; 100ml,
40/60, 30/min)ventilations. Furthermore, the Idehaler Pocket nebulizer was tested
in accordance with the European pharmacopoeia. Results: There was a statistical
difference between the Idehaler Pocket nebulizer and the others nebulizers for
adult and child models (p< 0.00001). Every tested nebulizers produced a MMAD
between 3mm and 5mm demonstrating the optimal particle size for CF patient.
Results obtained in accordance with the pharmacopoeia showed an inhaled fraction
of 68% ± 2% and a MMAD of 4.0mm±0.7mm for Idehaler pocket nebulizer.
Conclusion: The new antibiotic (3ml) can be nebulized with a high efﬁciency in
terms of aerosol performances when it used with the Idehaler Pocket nebulizer.
Supported by: Erempharma
Nebulizer Model Inhaled fraction (%) MMAD (mm) Nebulization time (min)
Idehaler Pocket Adult 61±4 4.8±0.3 7±1
Pari LC Sprint Adult 35±5 4.2±0.3 5±1
Eﬂow rapid Adult 27±3 3.8±0.4 5±1
Idehaler Pocket Child 30±3 4.8±0.3 7±1
Pari LC Sprint Child 14±1 4.2±0.2 8±1
Atomisor NL9M Child 10±1 4.9±0.1 7±1
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While the severity of airway obstruction increases, the predominant site of aerosol
deposition becomes the central airways. Positive expiratory pressure (PEP) is used
in patients presenting airway disease to reduce airway collapse during expiration.
Its combination with nebulization could increase lung deposition during expiratory
phase.
Objective: To compare inhaled dose delivered by a classical jet nebulizer (LC
Sprint Star; Pari) used alone (C) or coupled to positive expiratory pressure device
(Pari PEP S-System; Pari) (nPEP).
Method: Nebulizers (C and nPEP) were connected to a lung model (5600i Dual
Adult Training/Test Lung, Michigan Instrument Inc.) simulating usual breathing
pattern of an adult. PEP was monitored between 10 and 20 cm H2O.
A dried ﬁlter was interposed between the nebulizer and the lung model. The ﬁlter
was weighted before and 24 h after nebulization of amikacin (500mg/4mL). The
nebulizer output was calculated by assessing the amount of solution retained on
the ﬁlter paper. The drug output was calculated by multiplying the nebulizer output
and the relative mass of the drug.
Results: The inhaled dose (% of the nominal dose) was signiﬁcantly dif-
ferent between devices (34.1±7.2% vs 17.8±1.3% respectively for C and
nPEP)(p = 0.02). The output was higher for C than for nPEP (14.03±2.06mg/min
vs. 7.64±0.52mg/mL)(p = 0.006).
Conclusions: In these in vitro conditions, nebulization combined with a positive
expiratory pressure seems less efﬁcient than nebulization used alone. Lung compli-
ance must be taken into account.
